Retatrutide is still investigational, while tirzepatide and semaglutide are FDA-approved
Another study found that patients with type 2 diabetes and kidney disease who were prescribed GLP-1s had a 39% higher risk of requiring kidney replacement therapy (dialysis or transplant), compared to patients taking SGLT2 inhibitors
LIR, Liraglutide
the timing, outcome or impact of this announcement on ongoing litigation, governmental actions or regulatory statements
However, with the progression of research, it has become evident that GLP-1R is broadly distributed across various organs and tissues, including but not limited to the brain, heart, kidneys, intestines, eyes, and the vascular system (Song et al., 2017)
The future is focused on multi-pathway targeting